The Optimer delivery vehicle was developed to selectively target cells linked to fibrotic liver disease, as part of a fee-for-service partnership with the pharmaceutical company that began in 2020.

The Yorl business said it is now signing multiple new contracts with global market-leading pharmaceutical companies ...

“This type of discovery is the ambition of every physician,” says Gorbach, a longtime professor at Tufts University School of Medicine and the chief scientific officer at Optimer Pharmaceuticals in ...

Aptamer Group, a developer of novel Optimer ® binders to enable innovation in the life sciences sector, says it is gaining ...

York-based biotech firm, the Aptamer Group, has reported “revenue growth, solid cash position and strong technical progress” ...

We have underscored the growing demand for Optimer technology and the rising ... diagnostic and pharmaceutical scientists. The group is also working in partnership with Neuro-Bio to develop ...